| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 08/07/2001 | US6271248 Substituted biphenysulfonamide endothelin antagonists |
| 08/07/2001 | US6271017 Genes of Heliciobacter pylori necessary for the regulation and maturation of urease and their use |
| 08/07/2001 | US6270992 Histidine kinase of Staphylococcus aureus |
| 08/07/2001 | US6270960 Detecting microorganism in sample; incubate sample with preferential polypeptide and detect binding of preferential antibody |
| 08/07/2001 | US6270759 Method of using IL-11 for treating gingivitis |
| 08/07/2001 | US6270755 Anionic polymers as toxin binders |
| 08/07/2001 | CA2015296C Pyranyl cyanoguanidine derivatives |
| 08/02/2001 | WO2001055430A1 17 human secreted proteins |
| 08/02/2001 | WO2001055337A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055219A2 scsCNTFR/NNT-1 FUSION PROTEIN |
| 08/02/2001 | WO2001055178A2 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 08/02/2001 | WO2001055152A1 BENZOXATHIEPINO[3,4-b]PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
| 08/02/2001 | WO2001055150A1 4-heteroaryl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055133A1 Substituted tryptophan derivatives |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055121A1 Azepine derivatives |
| 08/02/2001 | WO2001055119A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 08/02/2001 | WO2001055115A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055105A1 N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| 08/02/2001 | WO2001055094A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | WO2001054731A2 Ligand conjugates and methods for preparing same |
| 08/02/2001 | WO2001054725A1 Remedies and preventives for dental diseases |
| 08/02/2001 | WO2001054718A2 Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions |
| 08/02/2001 | WO2001054711A2 Use of neurotoxins for treating diabetes |
| 08/02/2001 | WO2001054704A1 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| 08/02/2001 | WO2001054696A1 In vivo stain compounds and methods of use to identify dysplastic tissue |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001014548A3 New g-protein coupled receptor and dna sequences thereof |
| 08/02/2001 | WO2001014330A3 Phenylpiperazines as serotonin reuptake inhibitors |
| 08/02/2001 | WO2001012797A3 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2000076971A3 Serine protease inhibitors |
| 08/02/2001 | WO2000067847A3 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO2000047603A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011097 Methods and compositions for treating and preventing mucositis |
| 08/02/2001 | US20010011093 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 08/02/2001 | US20010011091 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | US20010010825 Rapidly disintegrable solid preparation |
| 08/02/2001 | US20010010821 For treatment of gastrointestinal disorders |
| 08/02/2001 | EP1144431A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | DE10004157A1 New pyridyl- or pyrimidinyl-substituted bicyclic pyrrole derivatives, are cyclokine release inhibitors useful for treating immune system-related disorders, e.g. cancer, multiple sclerosis or arthritis |
| 08/02/2001 | CA2401590A1 Physiologically balanced, ionized, acidic solution and methodology for use in wound healing |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398615A1 Benzoxathiepino[3,4-b]pyridine derivatives, process for their preparation and their use as medicaments |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398548A1 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398428A1 Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions |
| 08/02/2001 | CA2398227A1 17 human secreted proteins |
| 08/02/2001 | CA2397758A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2395832A1 Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| 08/02/2001 | CA2366759A1 In vivo stain compounds and methods of use to identify dysplastic tissue |
| 08/01/2001 | EP1120723A2 Identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists and associated pharmacophore models and screening methods |
| 08/01/2001 | EP1119643A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-$g(a) (TNF-$g(a)) EXPRESSION |
| 08/01/2001 | EP1119573A2 Bipyridine manganese complexes |
| 08/01/2001 | EP1119571A2 Tricyclic delta3-piperidines as alpha2-antagonists |
| 08/01/2001 | EP1119563A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119552A1 Ureidopiperidine derivatives as selective human nk 3? receptor antagonists |
| 08/01/2001 | EP1119551A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119544A1 Energetic nitramine-linked azoles and hydroxylammonium salts as oxidizers, initiators and gas generators |
| 08/01/2001 | EP1119543A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119538A1 Derivatives of phenantrene for medicinal use and a process for their preparation |
| 08/01/2001 | EP1119360A1 Methods and compositions for increasing intestinal absorption of fats |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119351A2 Use of catechol derivatives as proteinase inhibitors |
| 08/01/2001 | EP0885013B1 Use of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses for the preparation of medicaments |
| 08/01/2001 | EP0862567B1 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 08/01/2001 | EP0737074B1 Botulinum toxins for treating hyperhydrosis |
| 08/01/2001 | EP0631503B1 Use of vasoactive intestinal peptide (vip) to induce temporary paralysis of the gastrointestinal tract |
| 08/01/2001 | CN1306568A Human bile salt-stimulated lipase (BSSL) obtainable from transgenic sheep |
| 08/01/2001 | CN1306533A Imidazo pyridine derivatives which inhibit gastric acid secretion |
| 08/01/2001 | CN1306530A Paroxetine 10-camphorsulfonate for treament of CNS disorders |
| 08/01/2001 | CN1306512A Heterocyclic inhibitors of P38 |
| 08/01/2001 | CN1306433A Use of chemically-stabilized chlorite solution for inhibiting antigen-specific immune response |
| 08/01/2001 | CN1306428A Inhibitors of transcription factor NF-KB |
| 08/01/2001 | CN1306416A Desensitizing dentifrice contg. potassium and tin salts |
| 08/01/2001 | CN1306400A Drinks and foods capable of eliminating helicobacter pylori |
| 08/01/2001 | CN1305841A Medicine for treating gastrosis |
| 08/01/2001 | CN1305827A Chinese patent medicine for treating ulcer diseases |
| 08/01/2001 | CN1305814A Medicine for treating oral ulcer |
| 08/01/2001 | CN1305806A Orally applied solid preparation of medicine difficult to dissolve |
| 08/01/2001 | CN1305802A Oral desensitizing paste and its preparing process |
| 08/01/2001 | CN1069098C Novel imidazole derivative and process for producing same |
| 08/01/2001 | CN1069057C Chinese medicine for treating stomach diesease |